This article is more than 5 years old. Information may no longer be current.

FDA accepts Clearside’s NDA for Xipere suprachoroidal injection

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has accepted a new drug application for Xipere suprachoroidal injection for the treatment of macular edema associated with uveitis, according to a Clearside Biomedical press release.

“Macular edema is the leading cause of vision loss, and even blindness, in uveitis patients, and we are now one step closer to treating this underserved patient population,” Clearside President and CEO Daniel H. White said in the release. “Over the last several months, our team has worked diligently to reach this milestone, and we are now preparing to launch the product if approved.”

In the phase 3 PEACHTREE clinical trial, Xipere (triamcinolone acetonide ophthalmic suspension) was shown to improve vision in patients who had macular edema with noninfectious uveitis.

A PDUFA date has been set for Oct. 19.